Nuria Montserrat

Nuria Montserrat

Auto-generated profile, based on publicly available information

Nuria Montserrat

Pluripotency for organ regeneration (PR Lab), Institute for Bioengineering of Catalonia, The Barcelona Institute of Science and Technology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Cell
Verified
Journal Article
Closed access
VMVanessa Monteil
Vanessa Monteil
HKHyesoo Kwon
Hyesoo Kwon
PPPatricia Prado
Patricia Prado
AHAstrid Hagelkrüys
Astrid Hagelkrüys
RWReiner A. Wimmer
Reiner A. Wimmer
JPJosef M Penninger
Josef M Penninger

2 March 2011 in Nature
Verified
Journal Article
Open access
PDF file
AGAthurva Gore
Athurva Gore
ZLZhe Li
Zhe Li
HFHo-Lim Fung
Ho-Lim Fung
JYJessica E. Young
Jessica E. Young
SASuneet Agarwal
Suneet Agarwal
KZKun Zhang
Kun Zhang
Defined transcription factors can induce epigenetic reprogramming of adult mammalian cells into induced pluripotent stem cells. Although DNA factors are integrated during some reprogramming methods, it is unknown whether the genome remains unchanged at the single nucleotide level. Here we show that 22 human induced pluripotent stem (hiPS) cell lines reprogrammed using five different methods each contained an average of five protein-coding point mutations in the regions sampled (an estimated six protein-coding point mutations per exome). The majority of these mutations were non-synonymous, nonsense or splice variants, and were enriched in genes mutated or having causative effects in cancers. At least half of these reprogramming-associated mutations pre-existed in fibroblast progenitors at low frequencies, whereas the rest occurred during or after reprogramming. Thus, hiPS cells acquire genetic modifications in addition to epigenetic modifications. Extensive genetic screening should become a standard procedure to ensure hiPS cell safety before clinical use.

1 October 2009 in Cell Stem Cell
Verified
Journal Article
Closed access
AGAlessandra Giorgetti
Alessandra Giorgetti
NMNuria Montserrat
Nuria Montserrat
Trond AasenTrond Aasen
Trond Aasen
FGFederico Gonzalez
Federico Gonzalez
IRIgnacio Rodríguez-Pizà
Ignacio Rodríguez-Pizà
Juan Carlos Izpisua BelmonteJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte

17 November 2013 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YXYun Xia
Yun Xia
ENEmmanuel Nivet
Emmanuel Nivet
ISIgnacio Sancho-Martinez
Ignacio Sancho-Martinez
TGThomas Gallegos
Thomas Gallegos
KSKeiichiro Suzuki
Keiichiro Suzuki
JBJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte

16 November 2020 in Nature Materials
Verified
Journal Article
Closed access
PDF file
EGElena Garreta
Elena Garreta
RKRoger D Kamm
Roger D Kamm
SLSusana Chuva De Sousa Lopes
Susana Chuva De Sousa Lopes
MLMadeline A. Lancaster
Madeline A. Lancaster
RWRon Weiss
Ron Weiss
NMNuria Montserrat
Nuria Montserrat

17 October 2012 in Nature
Verified
Journal Article
Open access
PDF file
GLGuang-Hui Liu
Guang-Hui Liu
JQJing Qu
Jing Qu
KSKeiichiro Suzuki
Keiichiro Suzuki
ENEmmanuel Nivet
Emmanuel Nivet
MLMo Li
Mo Li
Juan Carlos Izpisua BelmonteJuan Carlos Izpisua Belmonte
Juan Carlos Izpisua Belmonte
Investigation of neural cells from post-mortem human brains and differentiated from patient-derived induced pluripotent stem cells shows that the LRRK2 mutation (G2019S) associated with familial and sporadic Parkinson's disease correlates with abnormalities at the nuclear envelope. The G2019S mutation in leucine-rich repeat kinase 2 (LRRK2) is associated with familial and sporadic Parkinson's disease, but the pathological mechanism involved is unclear. Here, Juan Carlos Izpisua Belmonte and colleagues report that neurons bearing the LRRK2(G2019S) mutation have profound abnormalities at the nuclear envelope. The authors validate this finding in neurons differentiated from patient-derived induced pluripotent stem cells, as well as in neurons from postmortem brains. These findings associate the nucleus with Parkinson's disease pathology, and have implications for diagnosis and the potential development of targeted therapeutics. Nuclear-architecture defects have been shown to correlate with the manifestation of a number of human diseases as well as ageing1,2,3,4. It is therefore plausible that diseases whose manifestations correlate with ageing might be connected to the appearance of nuclear aberrations over time. We decided to evaluate nuclear organization in the context of ageing-associated disorders by focusing on a leucine-rich repeat kinase 2 (LRRK2) dominant mutation (G2019S; glycine-to-serine substitution at amino acid 2019), which is associated with familial and sporadic Parkinson’s disease as well as impairment of adult neurogenesis in mice5. Here we report on the generation of induced pluripotent stem cells (iPSCs) derived from Parkinson’s disease patients and the implications of LRRK2(G2019S) mutation in human neural-stem-cell (NSC) populations. Mutant NSCs showed increased susceptibility to proteasomal stress as well as passage-dependent deficiencies in nuclear-envelope organization, clonal expansion and neuronal differentiation. Disease phenotypes were rescued by targeted correction of the LRRK2(G2019S) mutation with its wild-type counterpart in Parkinson’s disease iPSCs and were recapitulated after targeted knock-in of the LRRK2(G2019S) mutation in human embryonic stem cells. Analysis of human brain tissue showed nuclear-envelope impairment in clinically diagnosed Parkinson’s disease patients. Together, our results identify the nucleus as a previously unknown cellular organelle in Parkinson’s disease pathology and may help to open new avenues for Parkinson’s disease diagnoses as well as for the potential development of therapeutics targeting this fundamental cell structure.